Due to the special nature of medicines, returns and exchanges are not supported.
Final delivery from the nearest overseas warehous NEW

Ofatumumab Injection

Ofatumumab injection is a recombinant human monoclonal immunoglobulin G1 (IgG1) antibody, which is mainly used to treat relapsing multiple sclerosis (RMS) in adults.
This product is contraindicated in patients with active HBV confirmed by positive results of hepatitis B surface antigen [HBsAg] and anti-HBV tests.
An evaluation is required before the first use of this product, including hepatitis B virus (HBV) screening, serum immunoglobulin testing and immuno… Details 
Comprehensive interpretation of Ofatumumab injection

This product is mainly used to treat relapsing multiple sclerosis (RMS) in adults, including clinically isolated syndrome, relapsing-remitting multiple sclerosis and active secondary progressive multiple sclerosis.
Dosage and administration:
Evaluate before the first use of the drug: Hepatitis B virus screening: Hepatitis B virus (HBV) screening is performed before starting ofatumumab treatment. Ofatumumab injection is contraindicated in patients with active HBV confirmed by positive results of hepatitis B surface antigen [HBsAg] and anti-HBV tests. For HBV carriers who are HBsAg negative and positive for hepatitis B core antibody [HBcAb+], or [HBsAg+], consult a hepatologist before and during treatment with ofatumumab. Serum immunoglobulins: Before starting ofatumumab, perform quantitative serum immunoglobulin testing. For patients with low serum immunoglobulin levels, consult an immunologist before starting ofatumumab. Vaccination: Because live attenuated or live vaccines are not recommended during treatment and after discontinuation until B cell levels return to normal, live or live attenuated vaccines should be administered at least 4 weeks before starting ofatumumab, and inactivated vaccines should be administered at least 2 weeks before starting ofatumumab, as per immunization guidelines. Recommended dose: Initial dose of 20 mg subcutaneously at weeks 0, 1, and 2. 20 mg subcutaneously once a month starting at week 4. Instructions for use: This product is for subcutaneous administration only. Ofatumumab injection is for self-administration by subcutaneous injection. Inject ofatumumab subcutaneously in the abdomen, thigh, or outer upper arm. Do not inject into moles, scars, stretch marks, or areas of tenderness, bruising, redness, scaling, or lumps on the skin. The first injection of ofatumumab should be given under the supervision of a healthcare professional who has received appropriate training. The ofatumumab prefilled autoinjector pen is for single use only and should be discarded after use. For complete dosing instructions, see Instructions for Use. Preparation of ofatumumab: For more detailed instructions on the preparation of ofatumumab, see the ofatumumab injection instructions for use. Before administering, remove the ofatumumab prefilled autoinjector pen from the refrigerator and allow it to reach room temperature for 15 to 30 minutes. Do not remove the needle cap until the prefilled injection solution has reached room temperature. Inspect the injectable drug product visually for particulate matter and discoloration before administration, if the solution and container permit. Do not use if the liquid contains visible foreign matter or is cloudy.
Contraindicated if allergic to this product
Related dosage forms: